Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odronextamab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Odronextamab - Regeneron Pharmaceuticals

Alternative Names: CD20xCD3 bispecific antibody - Regeneron Pharmaceuticals; Ordspono; REGN-1979; ZL-1307

Latest Information Update: 07 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase III Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase II B-cell lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 06 Dec 2025 Efficacy, pharmacodynamic and adverse event data from a phase III OLYMPIA-2 trial in Follicular lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
  • 06 Dec 2025 Efficacy and adverse events data from the phase II ELM-2 trial in Non-Hodgkin's lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Pharmacokinetics, pharmacodynamics, efficacy and safety data from a phase III OLYMPIA-5 trial in Follicular lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top